Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
2.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

3.

Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists.

Bernatsky S, Habel Y, Rahme E.

J Rheumatol. 2010 May;37(5):928-31. doi: 10.3899/jrheum.091107. Epub 2010 Apr 1.

PMID:
20360181
4.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V.

JAMA. 2006 May 17;295(19):2275-85. Review. Erratum in: JAMA. 2006 Jun 7;295(21):2482.

PMID:
16705109
5.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT.

Ann Rheum Dis. 2005 May;64(5):699-703. Epub 2005 Feb 4.

7.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
8.

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials.

Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ.

Ann Rheum Dis. 2009 Jul;68(7):1177-83. doi: 10.1136/ard.2008.094904. Epub 2008 Nov 19. Review.

PMID:
19019889
9.

Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.

Keystone EC.

J Rheumatol. 2011 Aug;38(8):1552-62. doi: 10.3899/jrheum.100995. Epub 2011 May 15. Review.

PMID:
21572154
10.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

11.

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.

Barnabe C, Martin BJ, Ghali WA.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):522-9. doi: 10.1002/acr.20371. Review.

12.

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N.

Ann Rheum Dis. 2009 May;68(5):648-53. doi: 10.1136/ard.2007.085852. Epub 2008 May 8.

PMID:
18467516
13.

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.

Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM.

Arthritis Rheum. 2008 Aug 15;59(8):1074-81. doi: 10.1002/art.23913.

14.
15.

Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis.

Katikireddi VS, Whittle SL, Hill CL.

Int J Rheum Dis. 2010 Feb 1;13(1):12-26. doi: 10.1111/j.1756-185X.2009.01457.x. Review.

PMID:
20374381
16.

Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients.

Ornetti P, Chevillotte H, Zerrak A, Maillefert JF.

Drugs Aging. 2006;23(11):855-60. Review.

PMID:
17109564
17.

Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.

Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C.

Autoimmun Rev. 2010 Jan;9(3):175-80. doi: 10.1016/j.autrev.2009.07.006. Epub 2009 Jul 30.

PMID:
19647103
18.

The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.

Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK.

Am J Med. 2014 Dec;127(12):1208-32. doi: 10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17.

PMID:
24950486
19.

Assessing infection risk with biologic agents in RA: methodological challenges.

Fisher MC, Greenberg JD.

Nat Rev Rheumatol. 2009 May;5(5):288-91. doi: 10.1038/nrrheum.2009.51.

PMID:
19412196
20.

The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials.

An MM, Zou Z, Shen H, Zhang JD, Cao YB, Jiang YY.

Eur J Clin Pharmacol. 2010 Jan;66(1):49-59. doi: 10.1007/s00228-009-0754-0. Epub 2009 Nov 21.

PMID:
19936725
Items per page

Supplemental Content

Write to the Help Desk